Table of Content

1 Report Overview
1.1 Nucleic Vaccine Definition
1.2 Market by Type
1.2.1 Global Nucleic Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Preventive Nucleic Vaccine
1.2.3 Therapeutic Nucleic Vaccine
1.3 Market Segment by Application
1.3.1 Global Nucleic Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Nucleic Vaccine Sales
2.1 Global Nucleic Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Nucleic Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Nucleic Vaccine Revenue by Region
2.3.1 Global Nucleic Vaccine Revenue by Region (2018-2024)
2.3.2 Global Nucleic Vaccine Revenue by Region (2024-2034)
2.4 Global Nucleic Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Nucleic Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Nucleic Vaccine Sales Quantity by Region
2.6.1 Global Nucleic Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Nucleic Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Nucleic Vaccine Sales Quantity by Manufacturers
3.1.1 Global Nucleic Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Nucleic Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Nucleic Vaccine Sales in 2022
3.2 Global Nucleic Vaccine Revenue by Manufacturers
3.2.1 Global Nucleic Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Nucleic Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Nucleic Vaccine Revenue in 2022
3.3 Global Nucleic Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Nucleic Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Nucleic Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Nucleic Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Nucleic Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Nucleic Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Nucleic Vaccine Sales Quantity by Type
4.1.1 Global Nucleic Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Nucleic Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Nucleic Vaccine Revenue by Type
4.2.1 Global Nucleic Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Nucleic Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Nucleic Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Nucleic Vaccine Price by Type
4.3.1 Global Nucleic Vaccine Price by Type (2018-2024)
4.3.2 Global Nucleic Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Nucleic Vaccine Sales Quantity by Application
5.1.1 Global Nucleic Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Nucleic Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Nucleic Vaccine Revenue by Application
5.2.1 Global Nucleic Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Nucleic Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Nucleic Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Nucleic Vaccine Price by Application
5.3.1 Global Nucleic Vaccine Price by Application (2018-2024)
5.3.2 Global Nucleic Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Nucleic Vaccine Sales by Company
6.1.1 North America Nucleic Vaccine Revenue by Company (2018-2024)
6.1.2 North America Nucleic Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Nucleic Vaccine Market Size by Type
6.2.1 North America Nucleic Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Nucleic Vaccine Revenue by Type (2018-2034)
6.3 North America Nucleic Vaccine Market Size by Application
6.3.1 North America Nucleic Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Nucleic Vaccine Revenue by Application (2018-2034)
6.4 North America Nucleic Vaccine Market Size by Country
6.4.1 North America Nucleic Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Nucleic Vaccine Revenue by Country (2018-2034)
6.4.3 North America Nucleic Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Nucleic Vaccine Sales by Company
7.1.1 Europe Nucleic Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Nucleic Vaccine Revenue by Company (2018-2024)
7.2 Europe Nucleic Vaccine Market Size by Type
7.2.1 Europe Nucleic Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Nucleic Vaccine Revenue by Type (2018-2034)
7.3 Europe Nucleic Vaccine Market Size by Application
7.3.1 Europe Nucleic Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Nucleic Vaccine Revenue by Application (2018-2034)
7.4 Europe Nucleic Vaccine Market Size by Country
7.4.1 Europe Nucleic Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Nucleic Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Nucleic Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Nucleic Vaccine Sales by Company
8.1.1 China Nucleic Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Nucleic Vaccine Revenue by Company (2018-2024)
8.2 China Nucleic Vaccine Market Size by Type
8.2.1 China Nucleic Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Nucleic Vaccine Revenue by Type (2018-2034)
8.3 China Nucleic Vaccine Market Size by Application
8.3.1 China Nucleic Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Nucleic Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Nucleic Vaccine Sales by Company
9.1.1 APAC Nucleic Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Nucleic Vaccine Revenue by Company (2018-2024)
9.2 APAC Nucleic Vaccine Market Size by Type
9.2.1 APAC Nucleic Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Nucleic Vaccine Revenue by Type (2018-2034)
9.3 APAC Nucleic Vaccine Market Size by Application
9.3.1 APAC Nucleic Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Nucleic Vaccine Revenue by Application (2018-2034)
9.4 APAC Nucleic Vaccine Market Size by Region
9.4.1 APAC Nucleic Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Nucleic Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Nucleic Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Nucleic Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Nucleic Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Nucleic Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Nucleic Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Nucleic Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Nucleic Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Nucleic Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Nucleic Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Nucleic Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Moderna
11.1.1 Moderna Company Information
11.1.2 Moderna Overview
11.1.3 Moderna Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Moderna Nucleic Vaccine Products and Services
11.1.5 Moderna Nucleic Vaccine SWOT Analysis
11.1.6 Moderna Recent Developments
11.2 CureVac
11.2.1 CureVac Company Information
11.2.2 CureVac Overview
11.2.3 CureVac Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 CureVac Nucleic Vaccine Products and Services
11.2.5 CureVac Nucleic Vaccine SWOT Analysis
11.2.6 CureVac Recent Developments
11.3 Inovio
11.3.1 Inovio Company Information
11.3.2 Inovio Overview
11.3.3 Inovio Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Inovio Nucleic Vaccine Products and Services
11.3.5 Inovio Nucleic Vaccine SWOT Analysis
11.3.6 Inovio Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Sanofi Nucleic Vaccine Products and Services
11.4.5 Sanofi Nucleic Vaccine SWOT Analysis
11.4.6 Sanofi Recent Developments
11.5 GSK
11.5.1 GSK Company Information
11.5.2 GSK Overview
11.5.3 GSK Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 GSK Nucleic Vaccine Products and Services
11.5.5 GSK Nucleic Vaccine SWOT Analysis
11.5.6 GSK Recent Developments
11.6 CNBG
11.6.1 CNBG Company Information
11.6.2 CNBG Overview
11.6.3 CNBG Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 CNBG Nucleic Vaccine Products and Services
11.6.5 CNBG Nucleic Vaccine SWOT Analysis
11.6.6 CNBG Recent Developments
11.7 Hualan Bio
11.7.1 Hualan Bio Company Information
11.7.2 Hualan Bio Overview
11.7.3 Hualan Bio Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Hualan Bio Nucleic Vaccine Products and Services
11.7.5 Hualan Bio Nucleic Vaccine SWOT Analysis
11.7.6 Hualan Bio Recent Developments
11.8 Zhifei Shengwu
11.8.1 Zhifei Shengwu Company Information
11.8.2 Zhifei Shengwu Overview
11.8.3 Zhifei Shengwu Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Zhifei Shengwu Nucleic Vaccine Products and Services
11.8.5 Zhifei Shengwu Nucleic Vaccine SWOT Analysis
11.8.6 Zhifei Shengwu Recent Developments
11.9 Liaoning Chengda
11.9.1 Liaoning Chengda Company Information
11.9.2 Liaoning Chengda Overview
11.9.3 Liaoning Chengda Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Liaoning Chengda Nucleic Vaccine Products and Services
11.9.5 Liaoning Chengda Nucleic Vaccine SWOT Analysis
11.9.6 Liaoning Chengda Recent Developments
11.10 BioKangtai
11.10.1 BioKangtai Company Information
11.10.2 BioKangtai Overview
11.10.3 BioKangtai Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 BioKangtai Nucleic Vaccine Products and Services
11.10.5 BioKangtai Nucleic Vaccine SWOT Analysis
11.10.6 BioKangtai Recent Developments
11.11 CanSinoBIO
11.11.1 CanSinoBIO Company Information
11.11.2 CanSinoBIO Overview
11.11.3 CanSinoBIO Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 CanSinoBIO Nucleic Vaccine Products and Services
11.11.5 CanSinoBIO Recent Developments
11.12 Walvax Biotechnology
11.12.1 Walvax Biotechnology Company Information
11.12.2 Walvax Biotechnology Overview
11.12.3 Walvax Biotechnology Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Walvax Biotechnology Nucleic Vaccine Products and Services
11.12.5 Walvax Biotechnology Recent Developments
11.13 Fosun Pharma
11.13.1 Fosun Pharma Company Information
11.13.2 Fosun Pharma Overview
11.13.3 Fosun Pharma Nucleic Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Fosun Pharma Nucleic Vaccine Products and Services
11.13.5 Fosun Pharma Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Nucleic Vaccine Value Chain Analysis
12.2 Nucleic Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Nucleic Vaccine Production Mode & Process
12.4 Nucleic Vaccine Sales and Marketing
12.4.1 Nucleic Vaccine Sales Channels
12.4.2 Nucleic Vaccine Distributors
12.5 Nucleic Vaccine Customers
13 Market Dynamics
13.1 Nucleic Vaccine Industry Trends
13.2 Nucleic Vaccine Market Drivers
13.3 Nucleic Vaccine Market Challenges
13.4 Nucleic Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Nucleic Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Preventive Nucleic Vaccine
Table 3. Major Manufacturers of Therapeutic Nucleic Vaccine
Table 4. Global Nucleic Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Nucleic Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Nucleic Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Nucleic Vaccine Revenue Market Share by Region (2018-2024)
Table 8. Global Nucleic Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Nucleic Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Nucleic Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Nucleic Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Nucleic Vaccine Sales Market Share by Region (2018-2024)
Table 13. Global Nucleic Vaccine Sales by Region (2024-2034) & (K Units)
Table 14. Global Nucleic Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Nucleic Vaccine Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Nucleic Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Nucleic Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Nucleic Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Nucleic Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 20. Global Key Players of Nucleic Vaccine, Industry Ranking, 2021 VS 2022
Table 21. Global Nucleic Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Nucleic Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nucleic Vaccine as of 2022)
Table 23. Global Key Manufacturers of Nucleic Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Nucleic Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Nucleic Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Nucleic Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Nucleic Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Nucleic Vaccine Sales Quantity Share by Type (2018-2024)
Table 30. Global Nucleic Vaccine Sales Quantity Share by Type (2024-2034)
Table 31. Global Nucleic Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Nucleic Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Nucleic Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Nucleic Vaccine Revenue Share by Type (2024-2034)
Table 35. Nucleic Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Nucleic Vaccine Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Nucleic Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Nucleic Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Nucleic Vaccine Sales Quantity Share by Application (2018-2024)
Table 40. Global Nucleic Vaccine Sales Quantity Share by Application (2024-2034)
Table 41. Global Nucleic Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Nucleic Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Nucleic Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Nucleic Vaccine Revenue Share by Application (2024-2034)
Table 45. Nucleic Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Nucleic Vaccine Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. North America Nucleic Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Nucleic Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Nucleic Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Nucleic Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Nucleic Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Nucleic Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Nucleic Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Nucleic Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Nucleic Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Nucleic Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Nucleic Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Nucleic Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Nucleic Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Nucleic Vaccine Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Nucleic Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Nucleic Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Nucleic Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Nucleic Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Nucleic Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Nucleic Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Nucleic Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Nucleic Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Nucleic Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Nucleic Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Nucleic Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Nucleic Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Nucleic Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Nucleic Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Nucleic Vaccine Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Nucleic Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Nucleic Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Nucleic Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Nucleic Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Nucleic Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Nucleic Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Nucleic Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Nucleic Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Nucleic Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Nucleic Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Nucleic Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Nucleic Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Nucleic Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Nucleic Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Nucleic Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Nucleic Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Nucleic Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Nucleic Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Nucleic Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Nucleic Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Nucleic Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Nucleic Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Nucleic Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Nucleic Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Nucleic Vaccine Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Nucleic Vaccine Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Nucleic Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Moderna Company Information
Table 118. Moderna Description and Overview
Table 119. Moderna Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 120. Moderna Nucleic Vaccine Product and Services
Table 121. Moderna Nucleic Vaccine SWOT Analysis
Table 122. Moderna Recent Developments
Table 123. CureVac Company Information
Table 124. CureVac Description and Overview
Table 125. CureVac Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 126. CureVac Nucleic Vaccine Product and Services
Table 127. CureVac Nucleic Vaccine SWOT Analysis
Table 128. CureVac Recent Developments
Table 129. Inovio Company Information
Table 130. Inovio Description and Overview
Table 131. Inovio Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 132. Inovio Nucleic Vaccine Product and Services
Table 133. Inovio Nucleic Vaccine SWOT Analysis
Table 134. Inovio Recent Developments
Table 135. Sanofi Company Information
Table 136. Sanofi Description and Overview
Table 137. Sanofi Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 138. Sanofi Nucleic Vaccine Product and Services
Table 139. Sanofi Nucleic Vaccine SWOT Analysis
Table 140. Sanofi Recent Developments
Table 141. GSK Company Information
Table 142. GSK Description and Overview
Table 143. GSK Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 144. GSK Nucleic Vaccine Product and Services
Table 145. GSK Nucleic Vaccine SWOT Analysis
Table 146. GSK Recent Developments
Table 147. CNBG Company Information
Table 148. CNBG Description and Overview
Table 149. CNBG Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 150. CNBG Nucleic Vaccine Product and Services
Table 151. CNBG Nucleic Vaccine SWOT Analysis
Table 152. CNBG Recent Developments
Table 153. Hualan Bio Company Information
Table 154. Hualan Bio Description and Overview
Table 155. Hualan Bio Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 156. Hualan Bio Nucleic Vaccine Product and Services
Table 157. Hualan Bio Nucleic Vaccine SWOT Analysis
Table 158. Hualan Bio Recent Developments
Table 159. Zhifei Shengwu Company Information
Table 160. Zhifei Shengwu Description and Overview
Table 161. Zhifei Shengwu Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 162. Zhifei Shengwu Nucleic Vaccine Product and Services
Table 163. Zhifei Shengwu Nucleic Vaccine SWOT Analysis
Table 164. Zhifei Shengwu Recent Developments
Table 165. Liaoning Chengda Company Information
Table 166. Liaoning Chengda Description and Overview
Table 167. Liaoning Chengda Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 168. Liaoning Chengda Nucleic Vaccine Product and Services
Table 169. Liaoning Chengda Nucleic Vaccine SWOT Analysis
Table 170. Liaoning Chengda Recent Developments
Table 171. BioKangtai Company Information
Table 172. BioKangtai Description and Overview
Table 173. BioKangtai Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 174. BioKangtai Nucleic Vaccine Product and Services
Table 175. BioKangtai Nucleic Vaccine SWOT Analysis
Table 176. BioKangtai Recent Developments
Table 177. CanSinoBIO Company Information
Table 178. CanSinoBIO Description and Overview
Table 179. CanSinoBIO Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 180. CanSinoBIO Nucleic Vaccine Product and Services
Table 181. CanSinoBIO Recent Developments
Table 182. Walvax Biotechnology Company Information
Table 183. Walvax Biotechnology Description and Overview
Table 184. Walvax Biotechnology Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 185. Walvax Biotechnology Nucleic Vaccine Product and Services
Table 186. Walvax Biotechnology Recent Developments
Table 187. Fosun Pharma Company Information
Table 188. Fosun Pharma Description and Overview
Table 189. Fosun Pharma Nucleic Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 190. Fosun Pharma Nucleic Vaccine Product and Services
Table 191. Fosun Pharma Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Nucleic Vaccine Distributors List
Table 195. Nucleic Vaccine Customers List
Table 196. Nucleic Vaccine Market Trends
Table 197. Nucleic Vaccine Market Drivers
Table 198. Nucleic Vaccine Market Challenges
Table 199. Nucleic Vaccine Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Nucleic Vaccine Product Picture
Figure 2. Global Nucleic Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Nucleic Vaccine Market Share by Type in 2022 & 2034
Figure 4. Preventive Nucleic Vaccine Product Picture
Figure 5. Therapeutic Nucleic Vaccine Product Picture
Figure 6. Global Nucleic Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Nucleic Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Nucleic Vaccine Report Years Considered
Figure 12. Global Nucleic Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Nucleic Vaccine Revenue 2018-2034 (US$ Million)
Figure 14. Global Nucleic Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Nucleic Vaccine Sales Quantity 2018-2034 (K Units)
Figure 16. Global Nucleic Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Nucleic Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Nucleic Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Nucleic Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Nucleic Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Nucleic Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Nucleic Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Nucleic Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Nucleic Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Nucleic Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Nucleic Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Nucleic Vaccine Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Nucleic Vaccine Revenue in 2022
Figure 30. Nucleic Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Nucleic Vaccine Revenue Market Share by Type (2018-2034)
Figure 33. Global Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Nucleic Vaccine Revenue Market Share by Application (2018-2034)
Figure 35. North America Nucleic Vaccine Revenue Market Share by Company in 2022
Figure 36. North America Nucleic Vaccine Sales Quantity Market Share by Company in 2022
Figure 37. North America Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Nucleic Vaccine Revenue Market Share by Type (2018-2034)
Figure 39. North America Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Nucleic Vaccine Revenue Market Share by Application (2018-2034)
Figure 41. North America Nucleic Vaccine Revenue Share by Country (2018-2034)
Figure 42. North America Nucleic Vaccine Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Nucleic Vaccine Sales Quantity Market Share by Company in 2022
Figure 46. Europe Nucleic Vaccine Revenue Market Share by Company in 2022
Figure 47. Europe Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Nucleic Vaccine Revenue Market Share by Type (2018-2034)
Figure 49. Europe Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Nucleic Vaccine Revenue Market Share by Application (2018-2034)
Figure 51. Europe Nucleic Vaccine Revenue Share by Country (2018-2034)
Figure 52. Europe Nucleic Vaccine Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. France Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. China Nucleic Vaccine Sales Quantity Market Share by Company in 2022
Figure 59. China Nucleic Vaccine Revenue Market Share by Company in 2022
Figure 60. China Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Nucleic Vaccine Revenue Market Share by Type (2018-2034)
Figure 62. China Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Nucleic Vaccine Revenue Market Share by Application (2018-2034)
Figure 64. APAC Nucleic Vaccine Sales Quantity Market Share by Company in 2022
Figure 65. APAC Nucleic Vaccine Revenue Market Share by Company in 2022
Figure 66. APAC Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Nucleic Vaccine Revenue Market Share by Type (2018-2034)
Figure 68. APAC Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Nucleic Vaccine Revenue Market Share by Application (2018-2034)
Figure 70. APAC Nucleic Vaccine Revenue Share by Region (2018-2034)
Figure 71. APAC Nucleic Vaccine Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. India Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Nucleic Vaccine Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Nucleic Vaccine Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Nucleic Vaccine Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Nucleic Vaccine Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Nucleic Vaccine Revenue Share by Country (2018-2034)
Figure 85. Brazil Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Nucleic Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. Nucleic Vaccine Value Chain
Figure 91. Nucleic Vaccine Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed